COVID-19 Population Immunity Webinar 2022
Hear information on COVID-19 immunity from local and international guest speakers
Australia did remarkably well containing the spread of COVID-19 before vaccines and treatments became available. The ‘COVID-zero' strategy successfully limited our exposure to the virus, resulting in a “COVID-naïve” population. However, the ever-increasing transmissibility of Omicron and its sub-variants has provided a new challenge.
Subsequently, it appears that Australia and other countries with COVID-naïve populations seem to experience worse COVID-19 outcomes from Omicron relative to countries whose populations had prior exposure, despite vaccination and treatment.
In this webinar, hosted in November 2022, we discussed the effectiveness and immunity derived from prior SARS-CoV-2 infection, from vaccination alone, and from a combination of prior infection and vaccination (hybrid immunity) to understand our population’s immunity and what the future might hold for the COVID-19 vaccination program.
The presentation is followed by a discussion, chaired by Professor Fiona Russell.
In this webinar, hosted in November 2022, we discussed the effectiveness and immunity derived from prior SARS-CoV-2 infection, from vaccination alone, and from a combination of prior infection and vaccination (hybrid immunity) to understand our...
In this webinar, hosted in November 2022, we discussed the effectiveness and immunity derived from prior SARS-CoV-2 infection, from vaccination alone, and from a combination of prior infection and vaccination (hybrid immunity) to understand our population’s immunity and what the future might hold for the COVID-19 vaccination program.
The presentation is followed by a discussion, chaired by Professor Fiona Russell.
Presenters
Professor Fiona Russell
Director of the Child and Adolescent Health PhD Program, Dept of Paediatrics, University of Melbourne.
Group Leader Asia-Pacific Health Research, Murdoch Children’s Research Institute
Professor Katie Flanagan
Head of Infectious Diseases, Launceston General Hospital, Tasmania
Director of the Tasmanian Vaccine Trial Centre, Clifford Craig Foundation, Launceston
Clinical Professor, School of Medicine, University of Tasmania
Adjunct Professor, School of Health and Biomedical Science, RMIT, Melbourne
President of the Australasian Society for Infectious Diseases
Dr Niklas Bobrovitz
Research Lead, SeroTracker, O'Brien Institute of Public Health, University of Calgary
Research Associate, Dept Critical Care Medicine, University of Calgary
MD Student, University Health Network, University of Toronto